

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Damien Roos-Weil,¹ Philippe Moreau,² Hervé Avet-Loiseau,³ Jean-Louis Golmard,⁴ Mathieu Kuentz,⁵ Stéphane Vigouroux,⁶ Gérard Socié,⁷ Sabine Furst,⁸ Jean Soulier,⁹ Steven Le Gouill,² Sylvie François,¹⁰ Anne Thiebaut,¹¹ Agnès Buzyn,¹² Natacha Maillard,¹³ Ibrahim Yakoub-Agha,¹⁴ Nicole Raus,¹⁵ Jean-Paul Fermand,¹⁶ Mauricette Michallet,¹⁷ Didier Blaise,⁸ and Nathalie Dhédin¹ for the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

¹Hematology Department, University Hospital Pitié-Salpêtrière, Paris; ²Hematology Department, University Hospital, Nantes; ³Hematology Laboratory, University Hospital, Nantes; ⁴Statistical Unit, University Hospital Pitié-Salpêtrière, Paris; ⁵Hematology Department, University Hospital Henri Mondor, Créteil; ⁶Hematology Department, University Hospital, Bordeaux; ⁷Hematology Department, University Hospital Saint-Louis, Paris; ⁸Hematology Department, University Hospital, Marseille; ⁹Cytogenetic Laboratory, University Hospital Saint-Louis, Paris; ¹⁰Hematology Department, University Hospital, Angers; ¹¹Hematology Department, University Hospital, Grenoble; ¹²Hematology Department, University Hospital Necker, Paris; ¹³Hematology Department, University Hospital, Poitiers; ¹⁴Hematology Department, University Hospital, Lille; ¹⁵Data-Manager, SFGM-TC; ¹⁶Immuno-hematology Department, University Hospital Saint-Louis, Paris, and ¹⁷Hematology Department, University Hospital Herriot, Lyon, France

Citation: Roos-Weil D, Moreau P, Avet-Loiseau H, Golmard J-L, Kuentz M, Vigouroux S, Socié G, Furst S, Soulier J, Le Gouill S, François S, Thiebaut A, Buzyn A, Maillard N, Yakoub-Agha I, Raus N, Fermand J-P, Michallet M, Blaise D, and Dhédin N for the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 2011;96(10):1504-1511. doi:10.3324/haematol.2011.042713

Online Supplementary Table S1. Incidence of cytogenetic abnormalities in the study population.

<i>FISH analysis</i>	Incidence, n (%)	N. (%) of patients screened for the abnormality
del(13q)	84 (59)	141 (99)
t(4;14)	31 (25)	123 (86)
del(17p)	24 (25)	95 (66)
t(11;14)	24 (24)	97 (68)
t(14;16)	4 (4)	104 (73)

Online Supplementary Table S2. Post-transplant responses by disease status at time of allo-SCT.

Disease status at allo-SCT	Outcome					Total
	CR + VGPR	PR	SD + PD	N/A	N/E	
CR + VGPR	15	2	3	6	2	27
PR	35	28	9	13	5	92
SD + PD	5	4	4	9	2	24
N/A	1	0	1	0	0	1
Total	56	34	16	28	9	143

CR: complete remission; N/A, not available; N/E: not evaluable; PD: progressive disease; PR: partial response; SD: stable disease; VGPR: very good partial response.

Online Supplementary Figure S1. (A,B,C) Progression-free survival (PFS) and (D,E,F) overall survival (OS) according to cytogenetic abnormalities. (A) PFS for patients with (black) or without (red) del(13q), (B) with (black) or without (red) del(17p) and (C) with (black) or without (red) t(4;14). (D) OS for patients with or without del(13q), (E) with or without del(17p) and (F) with or without t(4;14).

